JNJ · News · 20260828N
Icotyde China Approval
JOHNSON & JOHNSON · 2026-08-28 · Importance 38 · Surprise 60 · In source text
Johnson & Johnson received approval from China’s National Medical Products Administration for Icotyde, an oral psoriasis treatment developed with Protagonist Therapeutics. The once-daily pill is intended to treat plaque psoriasis, a skin-related autoimmune disease. The approval establishes a regulatory milestone for the product in the Chinese market and expands J&J’s autoimmune-product presence in China.
Key facts
- Johnson & Johnson has received approval from China's National Medical Products Administration for Icotyde, an oral pill developed with Protagonist Therapeutics. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Johnson & Johnson has received approval from China's National Medical Products Administration for Icotyde, an oral pill developed with… |